natgillin/translations-raw huggingface dataset:
It is therefore recommended that no other vaccines should be administered on the same day or at different times.
Zato odsvetujemo dajanje drugih cepiv isti dan ali ob različnih časih.
Bottle of 10 ml (10 doses), 50 ml (50 doses), 100 ml (100 doses), or 250 ml (250 doses) packed individually in a cardboard box.
Plastenke po 10 ml (10 odmerkov), 50 ml (50 odmerkov), 100 ml (100 odmerkov) ali 250 ml (250 odmerkov), posamično pakirane v kartonaste škatle.
What is Locatim?
Kaj je zdravilo Locatim?
Locatim is an oral solution produced from colostrum which is given to calves in the first 12 hours of life.
Zdravilo Locatim je peroralna raztopina, ki se jo pridobiva iz kolostruma in se jo daje teletom v prvih 12 urah življenja.
It contains specific immunoglobulins G (a type of antibody) against Escherichia coli F5 adhesin as its active substance.
Zdravilna učinkovina zdravila so specifični imunoglobulini G (vrsta protiteles) proti adhezinu Escherichia coli F5.
These immunoglobulins protect calves against disease caused by bacteria.
Omenjeni imunoglobulini ščitijo teleta pred boleznijo, ki jo povzroča ta bakterija.
Locatim is presented in a 60 ml glass bottle.
Zdravilo Locatim je na voljo v 60 ml steklenici.
What is Locatim used for?
Za kaj se zdravilo Locatim uporablja?
Locatim is used to reduce death in newborn calves caused by enterotoxicosis due to the bacterium E. coli during the first days of life.
Zdravilo Locatim se uporablja za zmanjševanje smrtnosti novorojenih telet zaradi enterotoksikoze, ki jo povzroča bakterija E. coli v prvih dneh po telitvi.
Enterotoxicosis is a disease caused by the release of toxins in the body, with the main symptom being diarrhoea.
Enterotoksikoza je bolezen, ki jo povzroča sproščanje strupov v telesu in katere glavni simptom je diareja.
Locatim is given to calves less than 12 hours old, preferably within the first four hours after birth, as a supplement to natural colostrum (first milk) that the calves receive from their mother.
Zdravilo Locatim se daje teletom, starim manj kot 12 ur, najbolje v prvih urah po telitvi, kot dodatek naravnemu kolostrumu (prvo mleko), ki ga teleta prejmejo od svojih mater.
The dose of 60 ml (one vial) may be given alone or dissolved in milk or milk substitute.
Odmerek 60 ml (eno vialo) dajemo samostojno ali raztopljeno v mleku oziroma mlečnem nadomestku.
How does Locatim work?
Kako zdravilo Locatim deluje?
Locatim works by supplementing the protective properties of normal colostrum, the first milk made by cows after giving birth, which their calves drink during the first few hours of life.
Zdravilo Locatim je dopolnilo zaščitnim lastnostim običajnega kolostruma, t. j. mleka, ki ga krave proizvajajo, takoj ko skotijo, in ga teleta sesajo prvih nekaj ur svojega življenja.
Colostrum contains antibodies that help to protect the calves against certain infections.
Kolostrum vsebuje protitelesa, ki pomagajo teleta ščititi pred nekaterimi okužbami.
Locatim is made from colostrum from cows that have been immunised against E. coli, so that they produce antibodies in their colostrum.
Zdravilo Locatim se proizvaja iz kolostruma krav, ki so jih imunizirali proti E. coli, tako da v svojem kolostrumu ustvarjajo protitelesa.
The colostrum is collected and filtered and the lactoserum (the whey, the liquid part of milk) is concentrated to make Locatim.
Kolostrum se zbere in filtrira, mlečni serum (sirotka, sirna voda) pa se koncentrira in tako nastane zdravilo Locatim.
By providing additional antibodies against E. coli, calves receiving Locatim gain additional protection against this bacterium.
Teleta, ki prejemajo zdravilo Locatim, so tako zaradi oskrbe z dodatnimi protitelesi proti E. coli dodatno zaščitena proti tej bakteriji.
The natural uptake of colostrum within the first hours of life induces passive immunisation.
Naravni vnos kolostruma v prvih urah življenja sproži pasivno imunizacijo.
Locatim thereby provides additional protection against deaths due to enterotoxicosis caused by E. coli.
Zdravilo Locatim s tem zagotavlja dodatno zaščito pred smrtjo zaradi enterotoksikoze, ki jo povzroča E. coli.
How has Locatim been studied?
Kako je bilo zdravilo Locatim raziskano?
The results of field-based studies looking at diarrhoea in newborn calves are difficult to interpret, since diarrhoea has many causes and the severity of the disease depends on a variety of factors including, but not limited to, the nature and virulence of the organism(s) to which the calves are exposed and the general standards of hygiene and husbandry on the farm.
Rezultate terenskih študij, v katerih so raziskovali diarejo pri novorojenih teletih, je težko razlagati, ker ima diareja več vzrokov, resnost bolezni pa je odvisna od številnih dejavnikov, kot so na primer lastnosti in virulenca organizma (organizmov), ki so jim teleta izpostavljena, ter od splošnih higienskih standardov in živinorejske prakse na farmi.
(44-20) 74 18 84 00 Fax (44-20) 74 18 84 47 E-mail: mail@emea. europa. eu http: / /www. emea. europa. eu ©EMEA 2007 Reproduction and/ or distribution of this document is authorised for non commercial purposes only provided the EMEA is acknowledged What benefit has Locatim shown during the studies?
(44- 20) 74 18 84 00 Fax (44- 20) 74 18 84 47 E- mail: mail@ emea. europa. eu http: // www. emea. europa. eu ©EMEA 2007 Reproduction and/ or distribution of this document is authorised for non commercial purposes only provided the EMEA is acknowledged Kakšne koristi je zdravilo Locatim izkazalo med študijami?
In the laboratory-based study, calves receiving Locatim had less severe clinical signs of diarrhoea and better survival time than those that did not receive it.
V laboratorijskih študijah so imela teleta, ki so prejemala zdravilo Locatim, lažje klinične znake diareje in daljši čas preživetja kot tista, ki zdravila niso prejemala.
These results were confirmed in a field-based study.
Rezultati so bili potrjeni tudi v terenski študiji.
What is the risk associated with Locatim?
Kakšna tveganja so povezana z zdravilom Locatim?
There are no major side effects with Locatim.
Uporaba zdravila Locatim ne povzroča večjih neželenih učinkov.
There are no special precautions for Locatim.
Za zdravilo Locatim ni posebnih previdnostnih ukrepov.
Why has Locatim been approved?
Zakaj je bilo zdravilo Locatim odobreno?
The Committee for Medicinal Products for Veterinary Use (CVMP) concluded that the benefits of Locatim exceed the risks for the treatment of calves less than 12 hours of age to reduce mortality caused by enterotoxicosis associated with E. coli F5 (K99) adhesin during the first days of life as a supplement to colostrum from the dam, and recommended that Locatim be given a marketing authorisation.
Odbor je zato priporočil odobritev dovoljenja za promet z zdravilom Locatim.
The benefit-risk balance may be found in module 6 of this EPAR.
Razmerje med tveganji in koristmi najdete v modulu 6 tega evropskega javnega poročila o oceni zdravila (EPAR).
Other information about Locatim:
Druge informacije o zdravilu Locatim:
The European Commission granted a marketing authorisation valid throughout the European Union for Serinucoli to Biokema Anstalt on 29 March 1999.
Evropska komisija je dovoljenje za promet z zdravilom Serinucoli, veljavno po vsej Evropski uniji, odobrila družbi Biokema Anstalt dne 29. marca 1999.
The name of the medicine was changed to Locatim on 14 September 1999.
Ime zdravila je bilo dne 14. septembra 1999 spremenjeno v Locatim.
Invented Strength name
Izmišljeno ime
> 2.8log10 / ml bovine Oral solution concentrated lactoserum
> 2. 8log10 / ml goveji koncentrirani laktoserum
Neonatal calves less than 12 hours of age
Novorojena teleta Za peroralno do 12 ur starosti. dajanje
Type III glass 60 ml bottles
Stekleničko 60 ml stekla tipa III
1 bottle
1 Stekleničko Nič dni stekla
Active substance
Zdravilna( e) učinkovina( e):
Bovine concentrated lactoserum containing specific Immunoglobulins G against E. coli F5 (K99) adhesin ≥ 2.8* log10/ ml. * microagglutination method
Goveji koncentrirani laktoserum vsebuje specifične imunoglubuline G proti adhezinu E. coli ≥ 2. 8 * log10/ ml. * z metodo mikroaglutinacije
Excipient(s)
Pomožna( pomožne) snov( i):
Methyl parahydroxybenzoate ≤ 0.8 mg/ ml Propyl parahydroxybenzoate ≤ 0.2 mg/ ml
Metilparahidroksibenzoat ≤ 0. 8 mg/ ml Propilparahidroksibenzoat ≤ 0. 2 mg/ ml
Neonatal calves less than 12 hours of age
Novorojena teleta v starosti manj kot 12 ur.
Consequently, in addition to antibodies to E. coli F5 (K99) it also contains antibodies to other organisms, as a result of vaccination and/ or exposure of the donor cows to organisms in their environment.
Poleg protiteles proti E. coli F5 (K99) lahko posledično vsebuje tudi protitelesa na druge organizme, kar je posledica cepljenja ali/ in izpostavljenja donorskih krav organizmom v njihovem okolju.
None.
Navedba ni smiselna.
4.6 Adverse reactions (frequency and seriousness)
2/ 16 4. 6 Neželeni učinki (pogostost in resnost)
4.7 Use during pregnancy or lactation
4. 7 Uporaba v obdobju brejosti in laktacije
No information is available on the safety and efficacy of this product when used with any other veterinary medicinal product.
Ni podatkov o varnosti ter učinkovitosti ob sočasni uporabi tega zdravila s katerim koli drugim zdravilom za uporabo v veterinarski medicini.
A decision to use this product on the same day or at different times with any other veterinary medicinal product therefore needs to be made on a case by case basis.
Odločitev za sočasno uporabo tega zdravila isti dan ali ob drugem času kot druga zdravila za uporabo v veterinarski medicini mora biti zato sprejeta individualno za vsak primer posebej.
The product should be administered neat or diluted in milk or in milk replacer within the first 12 hours of the calf’ s life, preferably, as soon as it is receptive.
Zdravilo dajemo nerazredčeno ali razredčeno z mlekom ali mlečnim nadomestkom v prvih 12 urah po rojstvu.
Methyl parahydroxybenzoate Propyl parahydroxybenzoate
Metilparahidroksibenzoat Propilparahidroksibenzoat
3/ 17 6.2 Incompatibilities
6. 2 Inkompatibilnosti
In the absence of incompatibility studies this veterinary medicinal product must not be mixed with other veterinary medicinal products.
Zaradi pomanjkanja študij kompatibilnosti tega zdravila ne smemo mešati z drugimi zdravili za uporabo v veterinarski medicini.
6.4 Special precautions for storage
3/ 16 6. 4 Posebna navodila za shranjevanje
Biokema Anstalt, Pflugstrasse 12, 9490 Vaduz, Fürstentum Liechtenstein
Biokema Anstalt Pflugstrasse 12 9490 Vaduz Kneževina Lihtenštajn
Detailed information on this product is available on the website of the European Medicines Agency (EMEA) http: / /www. emea. europa. eu.
Podrobne informacije o tem zdravilu za uporabo v veterinarski medicini so na voljo na spletni strani Evropske agencije za zdravila (European Medicines Agency, EMEA) http: // www. emea. europa. eu /.
Any person intending to
Uvoz, prodaja, oskrba in/ ali uporaba Locatim je ali je lahko prepovedana v nekaterih državah članicah na njihovem celotnem ozemlju ali delu ozemlja v skladu z nacionalnim programom zdravstvenega varstva živali.
4/ 17 import, sell, supply and/ or use Locatim must consult the relevant Member State’ s competent authority on the current animal health policies prior to the import, sale, supply and/ or use.
Vsakdo, ki namerava uvažati, prodajati, oskrbovati in/ ali uporabljati Locatim, se mora posvetovati s pristojnimi organi posamezne države članice o veljavnih programih cepljenja še pred uvozom, prodajo, oskrbo in/ ali uporabo.
5/ 17 ANNEX II
4/ 16 DODATEK II
MANUFACTURER(S) OF THE BIOLOGICAL ACTIVE SUBSTANCE(S) AND MANUFACTURING AUTHORISATION HOLDER(S) RESPONSIBLE FOR BATCH RELEASE
5/ 16 A IZDELOVALEC (IZDELOVALCI) BIOLOŠKE ZDRAVILNE UČINKOVINE (ZDRAVILNIH UČINKOVIN) IN IMETNIK( I) DOVOLJENJ( A) ZA IZDELAVO ZDRAVILA, ODGOVOREN (ODGOVORNI) ZA SPROŠČANJE SERIJE
Name and address of the manufacturer(s) of the biological active substance(s)
Ime in naslov izdelovalca (izdelovalcev) biološke zdravilne učinkovine (zdravilnih učinkovin).
Biokema SA Chemin de la Chatanérie 2 1023 Crissier-Lausanne Switzerland
Biokema SA Chemin de la Chatanérie 2 Ch- 1023 Crissier- Lausanne Švica
Name and address of the manufacturer(s) responsible for batch release
Ime in naslov izdelovalca (izdelovalcev) zdravila, odgovornega za sproščanje serije
Merial Laboratoire Porte des Alpes Rue de l’ aviation 69800 Saint Priest France
Merial Laboratoire Porte des Alpes Rue de l’ Aviation 69800 Saint Priest Francija
Active substance specific immunoglobulins: not applicable
Zdravilna učinkovina specifične imunoglubuline: navedba ni smiselna.
The following excipients are included in Annex II of Council Regulation (EEC) No 2377/ 90 in accordance with the following table:
Naslednje pomožne snovi so vključen( i) v Dodatek II Uredbe Sveta (ES) No 2377/ 90 kot je navedeno v tabeli:
7/ 17 Pharmacologically active substance Calcium chloride1 Sodium chloride 2 Lactic acid 3 Sodium hydroxide 4 Sodium methyl hydroxybenzoate 5 Sodium propyl hydroxybenzoate 6 Sodium propionate 7 Propionic acid8
Živalska vrsta Vse živalske vrste, namenjene za prehrano ljudi
Animal Species All food-producing species All food- producing species All food-producing species All food- producing species All food-producing species All food- producing species All food-producing species All food- producing species
Vse živalske vrste, namenjene za prehrano ljudi
Other provisions
mlečna kislina3
Bovine concentrated lactoserum containing specific Immunoglobulins G against E. coli F5 (K99) adhesin ≥ 2.8 log10/ ml.
Goveji koncentrirani laktoserum vsebuje specifične imunoglubuline G proti adhezinu E. coli 28 * log10/ ml. * z metodo mikroaglutinacije
Batch{number}
lot {številka}
12/ 17 MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
11/ 16 PODATKI, KI MORAJO BITI NAJMANJ NAVEDENI NA MANJŠIH STIČNIH OVOJNINAH
Bovine concentrated lactoserum containing specific Immunoglobulin G against E. coli F5(K99) adhesion > 2.8 log 10/ ml
Goveji koncentrirani laktoserum vsebuje specifične imunoglubuline G proti adhezinu E. coli ≥ 2. 8 * log10/ ml. * z metodo mikroaglutinacije
Oral administration of 60ml as soon as possible, preferably given within the first 4 hours, but not later than 12 hours after birth.
Zdravilo dajemo čimprej peroralno v odmerku 60 ml, najbolje prve štiri ure in ne kasneje kot 12 ur po telitvi.
14/ 17 PACKAGE LEAFLET FOR:
13/ 16 NAVODILO ZA UPORABO
Merial Laboratoire Porte des Alpes Rue de l’ aviation 69800 Saint Priest France
Merial Laboratoire Porte des Alpes Rue de l’ aviation 69800 Saint Priest Francija
Reduction of mortality caused by enterotoxicosis associated with E. coli F5 (K99) adhesin during the first days of life as a supplement to colostrum from the dam,
Zmanjšanje stopnje umrljivosti zaradi enterotoksičnosti, ki jo povzroča adhezin E. coli F5 (K99) v prvih dneh po telitvi kot dodatek kolostrumu.
None
Niso znane
The product should be administered neat or diluted in milk or in milk replacer within the first 12 hours of the calf’ s life, preferably, as soon as it is receptive.
Zdravilo dajemo nerazredčeno ali razredčeno z mlekom ali mlečnim nadomestkom v prvih 12 urah po telitvi.
Store in a refrigerator (2 °C - 8 °C) Keep the bottle in the outer carton.
Shranjujte v hladilniku (2 C – 8 C).
Do not freeze.
Stekleničko shranjujte tesno zaprt.
Do not use after the expiry date stated on the label.
Ne shranjujte v zamrzovalniku.
Consequently, in addition to antibodies to E. coli F5 (K99) it also contains antibodies to other organisms, as a result of vaccination and/ or exposure of the donor cows to organisms in their environment.
Poleg protiteles proti E. coli F5 (K99) lahko posledično vsebuje tudi protitelesa proti drugim organizmom, kar je posledica cepljenja ali/ in izpostavljenja donorskih krav organizmom v njihovem okolju.
The import, sale, supply and/ or use of Locatim is or may be prohibited in certain Member States on the whole or part of their territory pursuant to National animal health policy.
Uvoz, prodaja, oskrba in/ ali uporaba Locatim je ali je lahko prepovedana v nekaterih državah članicah na njihovem celotnem ozemlju ali delu ozemlja v skladu z nacionalnim programom zdravstvenega varstva živali.
Any person intending to import, sell, supply and/ or use Locatim must consult the relevant Member State’ s competent authority on the current animal health policies prior to the import, sale, supply and/ or use.
Vsakdo, ki namerava uvažati, prodajati, oskrbovati in/ ali uporabljati Locatim, se mora posvetovati s pristojnimi organi posamezne države članice o veljavnih programih cepljenja še pred uvozom, prodajo, oskrbo in/ ali uporabo.
60 ml bottle.
60ml steklenička.
Loxicom is presented as a pale yellow oral suspension which is to be given mixed with food or directly into the mouth for dogs, or as a pale yellow solution for injection for use in dogs or cats.
Zdravilo Loxicom je na voljo v obliki bledo rumene peroralne suspenzije, ki se daje s hrano ali neposredno v usta psa, ali v obliki bledo rumene raztopine za injiciranje, ki se uporablja pri psih in mačkah.
Loxicom contains the active substance meloxicam in a strength of 0.5 mg/ ml or 1.5 mg/ ml for the oral suspension, and a strength of 5 mg/ ml for the solution for injection.
Zdravilo Loxicom vsebuje zdravilno učinkovino meloksikam v jakosti 0, 5 mg/ ml ali 1, 5 mg/ ml pri peroralni suspenziji in v jakosti 5 mg/ ml pri raztopini za injiciranje.
Loxicom is a ‘ generic ’ which means that Loxicom is similar to a ‘ reference veterinary medicine ’ already authorised in the EU (Metacam 1.5 mg/ ml oral suspension).
Zdravilo Loxicom je generično zdravilo, kar pomeni, da je podobno referenčnemu veterinarskemu zdravilu, ki je že odobreno v EU (zdravilu Metacam 1, 5 mg/ ml peroralna suspenzija).
Studies have been carried out to prove that Loxicom is ‘ bioequivalent ’ to the reference veterinary medicine which means that Loxicom is equivalent to Metacam 1.5 mg/ ml suspension in the way it is absorbed and used by the body.
Za dokazovanje biološke enakovrednosti zdravila Loxicom z referenčnim veterinarskim zdravilom so bile izvedene ustrezne študije, kar pomeni, da je zdravilo Loxicom enakovredno zdravilu Metacam 1, 5 mg/ ml suspenzija, in sicer po tem, kako ga telo absorbira in uporablja.
Loxicom is used in dogs to relieve inflammation and pain in musculo-skeletal disorders.
Zdravilo Loxicom se uporablja pri psih za lajšanje vnetja in bolečin pri kostno- mišičnih obolenjih.
It can be used for both acute disorders, such as those seen after an injury, and chronic (long term) disorders.
Lahko se uporablja tako za akutna obolenja, do katerih pride ob poškodbi, kot tudi za kronična (dolgotrajna) obolenja.
The solution for injection form is also used in dogs to reduce post-operative pain and inflammation following orthopaedic and soft tissue surgery or in cats to reduce post-operative pain after ovariohysterectomy (spaying) and minor soft tissue surgery.
Raztopina za injiciranje se uporablja pri psih tudi za lajšanje bolečin in vnetja po ortopedskih operacijah ali kirurških posegih na mehkih tkivih, ali pri mačkah za lajšanje bolečin po ovariohisterektomiji (kastriranju) in manjših kirurških posegih na mehkih tkivih.
Loxicom contains meloxicam, which belongs to a class of medicines called non-steroidal anti- inflammatory drugs (NSAIDs).
Zdravilo Loxicom vsebuje meloksikam, ki spada v skupino zdravil, ki jim pravimo nesteroidna protivnetna zdravila (NSAID).
How has the effectiveness of Loxicom been studied?
Kako je bila raziskana učinkovitost zdravila Loxicom?
A study looked at how Loxicom was absorbed and its effects in the body, in comparison with Metacam 1.5 mg/ ml oral suspension.
V študiji so preučevali absorbiranje zdravila Loxicom ter njegove učinke na telo v primerjavi z zdravilom Metacam 1, 5 mg/ ml peroralna suspenzija.
Reproduction is authorised provided the source is acknowledged What are the side-effects of Loxicom?
Kakšni so neželeni učinki zdravila Loxicom?
Occasional side effects of Loxicom are those seen with NSAIDs, such as loss of appetite, vomiting, diarrhoea, blood appearing in the stools, renal failure and apathy (lack of vitality).
Občasni neželeni učinki zdravila Loxicom so enaki kot pri drugih nesteroidnih protivnetnih zdravilih in obsegajo izgubo teka, bruhanje, drisko, kri v blatu, ledvično odpoved in apatijo (pomanjkanje vitalnosti).
These side effects occur generally within the first week of treatment and are usually temporary and disappear once treatment has stopped.
Ti neželeni učinki se običajno pojavijo v prvem tednu zdravljenja in so navadno začasni ter izzvenijo ob prenehanju zdravljenja.
In very rare cases they may be serious or fatal.
V zelo redkih primerih so lahko resni ali povzročijo smrtni izid.
In the case of the solution for injection form, in very rare cases anaphylactoid (hypersensitive allergic) reactions may occur and should be treated symptomatically.
Pri uporabi raztopine za injiciranje se lahko v zelo redkih primerih pojavijo anafilaktične (preobčutlivostne, alergične) reakcije, ki jih je treba zdraviti simptomatsko.
In the case of accidental ingestion or self-injection medical advice should be sought immediately, showing the package leaflet or label to the physician.
V primeru nenamernega zaužitja ali samoinjiciranja se takoj posvetujte z zdravnikom in mu pokažite navodilo za uporabo ali ovojnino.
The Committee for Medicinal Products for Veterinary Use (CVMP) considered that, in accordance with European Union requirements, Loxicom has been shown to be bioequivalent to Metacam 1.5 mg/ ml oral suspension.
Odbor za zdravila za uporabo v veterinarski medicini (CVMP) je menil, da se je zdravilo Loxicom v skladu z zahtevami Evropske unije izkazalo kot biološko enakovredno zdravilu Metacam 1, 5 mg/ ml peroralna suspenzija.
Therefore the CVMP’ s view was that, as for Metacam 1.5 mg/ ml oral suspension, Loxicom’ s benefits are greater than its risks when treating inflammation or pain in muscles or joints in dogs and they recommended that Loxicom should be given a marketing authorisation.
CVMP je zato menil, da so koristi zdravila Loxicom, tako kot pri zdravilu Metacam 1, 5 mg/ ml peroralna suspenzija, večje od z njim povezanih tveganj pri zdravljenju vnetij ali bolečin v mišicah ali sklepih pri psih, ter je priporočil, da se za zdravilo Loxicom odobri dovoljenje za promet.
Loxicom solution for injection has been formulated to be essentially similar to Metacam solution for injection.
Zdravilo Loxicom raztopina za injiciranje je bilo zasnovano tako, da je podobno zdravilu Metacam raztopina za injiciranje.
The benefit-risk balance may be found in module 6 of this EPAR.
Razmerje med koristmi in tveganji lahko najdete v modulu 6 tega evropskega javnega poročila o oceni zdravila (EPAR).
The European Commission granted a marketing authorisation valid throughout the European Union, for Loxicom to Norbrook Laboratories Limited on 10/ 02/ 2009.
Evropska komisija je dovoljenje za promet z zdravilom Loxicom, veljavno po vsej Evropski uniji, odobrila družbi Norbrook Laboratories Limited dne 10 / 02 / 2009.
February 2009
Povzetek je bil nazadnje posodobljen: februarju 2009
Page 2/ 2 ©EMEA 2009
2/ 2 ©EMEA 2009
Polyethylene terephtalate bottle, HDPE/ LDPE cap, polypropylene / polyethylene measuring syringe.
Polietilenska steklenička, z za otroke varnim zapiralom, polipropilenska/ polietilensk a merilna brizgalka
1 bottle with dosing syringe
1 steklenička z merilno brizgalko
Oral use
1, 5 mg/ ml
Solution for Injection
Raztopina za injiciranje
Dogs and Cats
Psi in mačke
1 glass vial
1 steklena viala
Loxicom 0.5 mg/ ml oral suspension for dogs Meloxicam
Loxicom 0, 5 mg/ ml, peroralna suspenzija za pse
Alleviation of inflammation and pain in both acute and chronic musculo-skeletal disorders in dogs.
Umirjanje vnetja in lajšanje bolečine pri akutnih in kroničnih mišično- skeletnih obolenjih.
Do not use in case of hypersensitivity to the active substance or to any of the excipients Do not use in dogs less than 6 weeks of age.
Ne uporabite pri psih, mlajših od 6 tednov.
4.4 Special warnings
Posebna opozorila za vsako ciljno živalsko vrsto
2/ 48 Special precautions to be taken by the person administering the veterinary medicinal product to animals
2/ 48 Posebni previdnostni ukrepi, ki jih mora izvajati oseba, ki živalim daje zdravilo